Our findings demonstrate that, for the first time, the in vivo inhibition of myostatin activity resulted in significant increases in both insulin sensitivity and fat consumption in Mstn−/− Meishan pigs, and thus provide very useful insight into the use of myostatin inhibitors as an effective alternative approach to treat obesity and type 2 diabetics. Here, MSTN is linked to type 2 diabetes mellitus.